Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma

Annals of Surgical Oncology

Volumn 11, Issue 7, 2004, Pages 705-713

  Withrow, Stephen J ^a,e   Liptak, Julius M ^a   Straw, Rodney C ^a   Dernell, William S ^a   Jameson, Vicki J ^a   Powers, Barbara E ^a   Johnson, Jeffery L ^b   Brekke, John H ^c   Douple, Evan B ^d  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Kensey Nash Corporation   (United States)

^d NATIONAL RESEARCH COUNCIL   (United States)

^e USA   (United States)

Author keywords

Limb sparing surgery; Local chemotherapy; Local tumor recurrence; Osteosarcoma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CEFALEXIN; CEFAZOLIN; CISPLATIN; COTRIMAZINE; METHACRYLIC ACID METHYL ESTER; POLYMER; BIOMATERIAL;

ADJUVANT CHEMOTHERAPY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; LIMB; LIMB SPARING SURGERY; MULTIVARIATE ANALYSIS; NONHUMAN; OSTEOSARCOMA; POSTOPERATIVE INFECTION; PROGNOSIS; STATISTICAL SIGNIFICANCE; ANIMAL; ANIMAL DISEASE; BIOREMEDIATION; BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOG DISEASE; FEMALE; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; BIODEGRADATION, ENVIRONMENTAL; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOG DISEASES; DOGS; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; POLYMERS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 16644379889     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.10.008     Document Type: Article

References (43)

1. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology. Philadelphia: WB Saunders, 2001:378-417.
2. LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734-44.
3. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop 1991;270: 159-68.
4. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996;26:135-43.
5. Kuntz CA, Asselin TL, Dernell WS, et al. Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet Surg 1998;27:417-22.
6. Morello E, Buracco P, Martano M, et al. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 2001;42:61-6.
7. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: a long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994;76:649-56.
8. Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 1996;324:86-97.
9. Sluga M, Windhager R, Lang S, et al. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop 1999;358:120-7.
10. Renard AJ, Veth RP, Schreuder HW, et al. Function and complications after ablative and limb-salvage therapy in lower extremity sarcoma of the bone. J Surg Oncol 2000;73:198-205.
11. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2001:1891-908.
12. DiCaprio MR, Friedlaender GE. Malignant bone tumors: limb sparing versus amputation. J Am Acad Orthop Surg 2003;11:25-37.
13. Nell MD, Shah N, Daw N, et al. Survival after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience, 1970-2000. Musculoskeletal Tum Soc Proc 2002.
14. Theon AP, Madewell BR, Moore AS, Stephens C, Krag DN. Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumors. Int J Hyperthermia 1991;7:881-92.
15. Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy experience in six dogs. J Vet Intern Med 1991;5:227-31.
16. Straw RC, Withrow SJ, Douple EB, et al. Effects of cis- diamminedichloroplatinum II released from D,L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res 1994; 12:871-7.
17. Kitchell RB, Brown DM, Luck EE, et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 1994;204:229-36.
18. Kitchell BK, Orenberg EK, Brown DM, et al. Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma. Eur J Cancer 1995;31:2093-8.
19. Dernell WS, Withrow SJ, Straw RC, et al. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res 1997;17:4499-506.
20. Morello E, Dernell WS, Kuntz CA, et al. Evaluation of cisplatin in combination with a biologic response modifier in a murine mammary carcinoma model. Cancer Invest 2002;20:480-9.
21. Kanno S, Hyodo M, Suzuli K, et al. Effect of DNA-damaging agents on DNA replication and cell-cycle progression of cultured mouse mammary carcinoma cells. Jpn J Cancer Res 1985;76:289-96.
22. Sevin B, Pollack A, Averate HE, et al. In vivo cell kinetic effects of cis-platinum on human cancer xenografts measured by dual parameter flow cytometry. Cytometry 1987;8:153-62.
23. Ehrhart N, Dernell WS, Ehrhart EJ, et al. Effects of a controlled-release cisplatin delivery system used after resection of mammary carcinoma in mice. Am J Vet Res 1999;60:1347-51.
24. Mauldin GN, Matus RE, Withrow SJ, Patnaik K. Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177-80.
25. Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-11.
26. Kraegel SA, Madewell BR, Simonson E, Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-9.
27. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991;5: 205-10.
28. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-8.
29. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-3.
30. Withrow SJ, Straw RC, Brekke JH, et al. Slow release adjuvant cisplatin for treatment of metastatic canine osteosarcoma. Eur J Musculoskeletal Res 1995;4:105-10.
31. Chun R, Kurzman ID, Cuoto CG, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 2000;14:495-8.
32. Knapp DW, Richardson RC, Bonney PL, Hahn K. Cisplatin ther apy in 41 dogs with malignant tumors. J Vet Intern Med 1988;2: 41-6.
33. Hardie EM, Page RL, Williams PL, Fischer WD. Effect of time of cisplatin administration on toxicity and pharmacokinetics in dogs. Am J Vet Res 1991;52:1821-5.
34. Ogilvie GK, Straw RC, Powers BE, et al. Prevalence of nephrotoxicosis associated with a short-term saline solution diuresis protocol for the administration of cisplatin to dogs with malignant tumors: 61 cases (1987-1989). J Am Vet Med Assoc 1991;199: 613-6.
35. Ogilvie GK, Fettman MJ, Jameson VJ, et al. Evaluation of one-hour saline diuresis protocol for administration of cisplatin to dogs. Am J Vet Res 1992;53:1666-9.
36. Ogilvie GK, Straw RC, Jameson VJ, et al. Prevalence of nephrotoxicosis associated with a four-hour saline solution diuresis protocol for the administration of cisplatin to dogs with naturally developing neoplasms. J Am Vet Med Assoc 1993;202: 1845-8.
37. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
38. Dernell WS, Withrow SJ, Straw RC, et al. Clinical response to antibiotic-impregnated polymethyl methacrylate bead implantation of dogs with severe osteomyelitis. Vet Comp Orthop Traumatol 1998;11:94-9.
39. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-60.
40. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
41. Liptak JM, Dernell WS, Lascelles BDX, et al. Survival analysis of dogs with appendicular osteosarcoma treated with limb sparing surgery and adjuvant carboplatin or carboplatin and doxorubicin. Vet Cancer Conf Proc 2001:39.
42. Leibman NF, Kuntz CA, Steyn PF, et al. Accuracy of radiography, nuclear scintigraphy, and histopathology for determining the proximal extent of distal radius osteosarcoma in dogs. Vet Surg 2001; 30:240-5.
43. Wallack ST, Wisner ER, Werner JA, et al. Accuracy of magnetic resonance imaging for estimating intramedullary osteosarcoma extent in preoperative planning of canine limb-salvage procedures. Vet Radiol Ultrasound 2002;43:432-41.